The risk of cardiac events in patients who received concomitant levofloxacin and amiodarone
Objectives: Levofloxacin and amiodarone are both known to prolong the QT interval. This study was conducted to estimate the risk of cardiac events in patients receiving concomitant levofloxacin and amiodarone. Methods: The study included patients who were admitted to a large academic community medic...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-01-01
|
| Series: | International Journal of Infectious Diseases |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971218345648 |
| _version_ | 1818648940857262080 |
|---|---|
| author | Luigi Brunetti Seung-Mi Lee Ronald G. Nahass David Suh Benjamin Miao John Bucek Dongwon Kim Ok-Kyu Kim Dong-Churl Suh |
| author_facet | Luigi Brunetti Seung-Mi Lee Ronald G. Nahass David Suh Benjamin Miao John Bucek Dongwon Kim Ok-Kyu Kim Dong-Churl Suh |
| author_sort | Luigi Brunetti |
| collection | DOAJ |
| description | Objectives: Levofloxacin and amiodarone are both known to prolong the QT interval. This study was conducted to estimate the risk of cardiac events in patients receiving concomitant levofloxacin and amiodarone. Methods: The study included patients who were admitted to a large academic community medical center from 1/2012 to 12/2015 and received both levofloxacin and amiodarone at some point during their hospitalization. Patients received concomitant or non-concomitant levofloxacin and amiodarone during hospitalization. The primary outcome was the occurrence of cardiac events during therapy. The secondary outcome was the proportion of patients with an electrocardiogram performed before and after initiation of therapy. Odds ratios for cardiac events were calculated using a multivariable logistic regression model with and without adjusting for the study variables. The concomitant group was further evaluated for predictors of the primary outcome using multivariable logistic regression. Results: This study included 240 patients, 164 (68.3%) of whom received concomitant levofloxacin and amiodarone. Concomitant medication therapy was associated with a greater than six-fold increased risk of cardiac events after adjusting for the study variables (Odds Ratio = 6.20; 95% Confidence Interval = 1.34–28.62). Conclusions: Patients receiving concomitant amiodarone and levofloxacin experienced a five-fold increase in cardiac events compared to patients given either medication alone. Keywords: Levofloxacin, Amiodarone, Cardiac risk, Cardiac death, QT interval |
| first_indexed | 2024-12-17T01:26:25Z |
| format | Article |
| id | doaj.art-b063aa564c014be99a9f1e6f7e5e9c5e |
| institution | Directory Open Access Journal |
| issn | 1201-9712 |
| language | English |
| last_indexed | 2024-12-17T01:26:25Z |
| publishDate | 2019-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj.art-b063aa564c014be99a9f1e6f7e5e9c5e2022-12-21T22:08:41ZengElsevierInternational Journal of Infectious Diseases1201-97122019-01-01785056The risk of cardiac events in patients who received concomitant levofloxacin and amiodaroneLuigi Brunetti0Seung-Mi Lee1Ronald G. Nahass2David Suh3Benjamin Miao4John Bucek5Dongwon Kim6Ok-Kyu Kim7Dong-Churl Suh8Rutgers University School of Pharmacy, Piscataway, NJ, USA; RWJ Barnabas Health-Robert Wood Johnson University Hospital Somerset, Somerville, NJ, USARutgers University School of Pharmacy, Piscataway, NJ, USA; Chung-Ang University College of Pharmacy, Seoul, South KoreaRutgers University School of Pharmacy, Piscataway, NJ, USA; RWJ Barnabas Health-Robert Wood Johnson University Hospital Somerset, Somerville, NJ, USAColumbia University School of Public Health, New York, NY, USARutgers University School of Pharmacy, Piscataway, NJ, USARWJ Barnabas Health-Robert Wood Johnson University Hospital Somerset, Somerville, NJ, USAChung-Ang University College of Pharmacy, Seoul, South KoreaChung-Ang University College of Pharmacy, Seoul, South KoreaChung-Ang University College of Pharmacy, Seoul, South Korea; Corresponding author at: Chung-Ang University College of Pharmacy, 84 Heukseok-ro, Dongjak-gu, Seoul 06974, South Korea.Objectives: Levofloxacin and amiodarone are both known to prolong the QT interval. This study was conducted to estimate the risk of cardiac events in patients receiving concomitant levofloxacin and amiodarone. Methods: The study included patients who were admitted to a large academic community medical center from 1/2012 to 12/2015 and received both levofloxacin and amiodarone at some point during their hospitalization. Patients received concomitant or non-concomitant levofloxacin and amiodarone during hospitalization. The primary outcome was the occurrence of cardiac events during therapy. The secondary outcome was the proportion of patients with an electrocardiogram performed before and after initiation of therapy. Odds ratios for cardiac events were calculated using a multivariable logistic regression model with and without adjusting for the study variables. The concomitant group was further evaluated for predictors of the primary outcome using multivariable logistic regression. Results: This study included 240 patients, 164 (68.3%) of whom received concomitant levofloxacin and amiodarone. Concomitant medication therapy was associated with a greater than six-fold increased risk of cardiac events after adjusting for the study variables (Odds Ratio = 6.20; 95% Confidence Interval = 1.34–28.62). Conclusions: Patients receiving concomitant amiodarone and levofloxacin experienced a five-fold increase in cardiac events compared to patients given either medication alone. Keywords: Levofloxacin, Amiodarone, Cardiac risk, Cardiac death, QT intervalhttp://www.sciencedirect.com/science/article/pii/S1201971218345648 |
| spellingShingle | Luigi Brunetti Seung-Mi Lee Ronald G. Nahass David Suh Benjamin Miao John Bucek Dongwon Kim Ok-Kyu Kim Dong-Churl Suh The risk of cardiac events in patients who received concomitant levofloxacin and amiodarone International Journal of Infectious Diseases |
| title | The risk of cardiac events in patients who received concomitant levofloxacin and amiodarone |
| title_full | The risk of cardiac events in patients who received concomitant levofloxacin and amiodarone |
| title_fullStr | The risk of cardiac events in patients who received concomitant levofloxacin and amiodarone |
| title_full_unstemmed | The risk of cardiac events in patients who received concomitant levofloxacin and amiodarone |
| title_short | The risk of cardiac events in patients who received concomitant levofloxacin and amiodarone |
| title_sort | risk of cardiac events in patients who received concomitant levofloxacin and amiodarone |
| url | http://www.sciencedirect.com/science/article/pii/S1201971218345648 |
| work_keys_str_mv | AT luigibrunetti theriskofcardiaceventsinpatientswhoreceivedconcomitantlevofloxacinandamiodarone AT seungmilee theriskofcardiaceventsinpatientswhoreceivedconcomitantlevofloxacinandamiodarone AT ronaldgnahass theriskofcardiaceventsinpatientswhoreceivedconcomitantlevofloxacinandamiodarone AT davidsuh theriskofcardiaceventsinpatientswhoreceivedconcomitantlevofloxacinandamiodarone AT benjaminmiao theriskofcardiaceventsinpatientswhoreceivedconcomitantlevofloxacinandamiodarone AT johnbucek theriskofcardiaceventsinpatientswhoreceivedconcomitantlevofloxacinandamiodarone AT dongwonkim theriskofcardiaceventsinpatientswhoreceivedconcomitantlevofloxacinandamiodarone AT okkyukim theriskofcardiaceventsinpatientswhoreceivedconcomitantlevofloxacinandamiodarone AT dongchurlsuh theriskofcardiaceventsinpatientswhoreceivedconcomitantlevofloxacinandamiodarone AT luigibrunetti riskofcardiaceventsinpatientswhoreceivedconcomitantlevofloxacinandamiodarone AT seungmilee riskofcardiaceventsinpatientswhoreceivedconcomitantlevofloxacinandamiodarone AT ronaldgnahass riskofcardiaceventsinpatientswhoreceivedconcomitantlevofloxacinandamiodarone AT davidsuh riskofcardiaceventsinpatientswhoreceivedconcomitantlevofloxacinandamiodarone AT benjaminmiao riskofcardiaceventsinpatientswhoreceivedconcomitantlevofloxacinandamiodarone AT johnbucek riskofcardiaceventsinpatientswhoreceivedconcomitantlevofloxacinandamiodarone AT dongwonkim riskofcardiaceventsinpatientswhoreceivedconcomitantlevofloxacinandamiodarone AT okkyukim riskofcardiaceventsinpatientswhoreceivedconcomitantlevofloxacinandamiodarone AT dongchurlsuh riskofcardiaceventsinpatientswhoreceivedconcomitantlevofloxacinandamiodarone |